Funds holding VOR BIOPHARMA INC
ISIN US9290332074 · United States
- Fund holders
- 110
- Of which ETFs
- 16 94 other funds
- Value held
- ≈ 239.4M $ 239.3M $ · 55.7K €
- Share of capital
- 21.2 % of 59.2M shares on Aug 6, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Knights of Columbus U.S. ALL CAP INDEX FUND ADVISORS' INNER CIRCLE III | 250 | 5.3K $ | 0.00 % | 0.00 % | as of Jul 31, 2026 ↗ |
| Russell 2000 2x Strategy Fund Rydex Dynamic Funds | 219 | 4K $ | 0.01 % | 0.00 % | as of Jun 30, 2026 ↗ |
| PROFUND VP ULTRA SMALL CAP ProFunds | 168 | 3.1K $ | 0.02 % | 0.00 % | as of Jun 30, 2026 ↗ |
| PROFUND VP SMALL CAP ProFunds | 109 | 2K $ | 0.02 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Russell 2000 Fund Rydex Series Funds | 101 | 1.9K $ | 0.01 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 63 | 1.2K $ | 0.03 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 60 | 1.1K $ | 0.02 % | 0.00 % | as of Jun 30, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 34 | 719.1 $ | 0.01 % | 0.00 % | as of Jul 31, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 12 | 220.9 $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 55.7K € | 0.07 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 0.99 % | as of Jul 31, 2026 ↗ |
| Select Biotechnology Portfolio Fidelity Select Portfolios | 0.34 % | as of May 31, 2026 ↗ |
| Fidelity Advisor Biotechnology Fund Fidelity Advisor Series VII | 0.33 % | as of Jul 31, 2026 ↗ |
| Fidelity Small Cap Discovery Fund Fidelity Concord Street Trust | 0.32 % | as of Jul 31, 2026 ↗ |
| Fidelity Series Small Cap Discovery Fund Fidelity Concord Street Trust | 0.32 % | as of Jul 31, 2026 ↗ |
| Fidelity Small Cap Growth Fund Fidelity Securities Fund | 0.31 % | as of Jul 31, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 0.30 % | as of Jun 30, 2026 ↗ |
| Fidelity Small Cap Growth K6 Fund Fidelity Securities Fund | 0.30 % | as of Jul 31, 2026 ↗ |
| BIOTECHNOLOGY ULTRASECTOR PROFUND ProFunds | 0.30 % | as of Jul 31, 2026 ↗ |
| PROFUND VP BIOTECHNOLOGY ProFunds | 0.29 % | as of Jun 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 109 | +77 | 12,553,813 | +181.6 % |
| 2026Q2 | 32 | +9 | 4,457,484 | +32.3 % |
| 2026Q1 | 23 | +11 | 3,370,344 | +2,841.3 % |
| 2025Q4 | 12 | 114,586 |
Institutional managers
77 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| TCG Crossover Management, LLC | 5,673,078 | 96.5M $ | as of Mar 31, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 5,404,998 | 96.4M $ | as of Mar 31, 2026 |
| FCPM III SERVICES B.V. | 4,117,354 | 73.5M $ | as of Mar 31, 2026 |
| Venrock Adviser, LLC | 3,041,719 | 54.3M $ | as of Mar 31, 2026 |
| Frazier Life Sciences Management, L.P. | 2,543,939 | 45.4M $ | as of Mar 31, 2026 |
| Caligan Partners LP | 1,925,066 | 34.3M $ | as of Mar 31, 2026 |
| GREAT POINT PARTNERS LLC | 1,750,000 | 31.2M $ | as of Mar 31, 2026 |
| Paradigm Biocapital Advisors LP | 1,750,000 | 31.2M $ | as of Mar 31, 2026 |
| FMR LLC | 1,539,670 | 27.5M $ | as of Mar 31, 2026 |
| MARSHALL WACE, LLP | 1,153,276 | 20.6M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 1,118,458 | 20M $ | as of Mar 31, 2026 |
| NEXTBio Capital Management LP | 999,967 | 17.8M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 794,759 | 14.2M $ | as of Mar 31, 2026 |
| Logos Global Management LP | 750,000 | 13.4M $ | as of Mar 31, 2026 |
| Rosalind Advisors, Inc. | 700,000 | 12.5M $ | as of Mar 31, 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 555,702 | 9.9M $ | as of Mar 31, 2026 |
| UBS Group AG | 488,368 | 8.7M $ | as of Mar 31, 2026 |
| BRAIDWELL LP | 466,774 | 8.3M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 342,573 | 6.1M $ | as of Mar 31, 2026 |
| Clearline Capital LP | 326,168 | 5.8M $ | as of Mar 31, 2026 |
| SPHERA FUNDS MANAGEMENT LTD. | 321,917 | 5.7M $ | as of Mar 31, 2026 |
| Laurion Capital Management LP | 318,670 | 5.7M $ | as of Mar 31, 2026 |
| Propel Bio Management, LLC | 314,543 | 5.6M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 261,891 | 4.7M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 258,587 | 4.6M $ | as of Mar 31, 2026 |
Declared shareholders of VOR BIOPHARMA INC
There are 6 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| RA Capital Management, L.P. and 3 others | 19.90 % | 12,937,855 | as of Jul 16, 2026 · SCHEDULE 13D |
| FMR LLC and 1 other | 12.00 % | 6,509,996 | as of Jul 31, 2026 · SCHEDULE 13G |
| Venrock Healthcare Capital Partners III, L.P. and 6 others | 9.90 % | 5,676,370 | as of Jun 30, 2026 · SCHEDULE 13G |
| Verve Capital Limited | 6.30 % | 3,410,892 | as of Jun 30, 2026 · SCHEDULE 13G |
| BlackRock, Inc. | 5.70 % | 3,099,259 | as of Jun 30, 2026 · SCHEDULE 13G |
| Frazier Life Sciences Public Fund, L.P. and 8 others | 4.20 % | 2,258,001 | as of Jun 30, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding VOR BIOPHARMA INC". https://titelia.com/en/stocks/vor-biopharma-inc-US9290332074